ELISA/assay

Guinea pig Vascular Endothelial Growth Factor ELISA Kit

MBS725983

48-Strip-Wells

470 USD

ELISA Kit

Guinea pig Vascular Endothelial Growth Factor ELISA Kit

Vascular Endothelial Growth Factor

vascular endothelial growth factor; Vascular endothelial growth factor A; vascular endothelial growth factor A; vascular permeability factor; vascular endothelial growth factor A; Vascular permeability factor; VPF

VEGF

VEGFA; VEGFA; VPF; VEGF; MVCD1; VEGF; VEGF-A; VPF

VEGFA_HUMAN

Guinea Pig

This assay has high sensitivity and excellent specificity for detection of VEGF. No significant cross-reactivity or interference between VEGF and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between VEGF and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 1.0 pg/mL.

Intended Uses: This VEGF ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Guinea pig VEGF. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Cancer

Principle of the assay: VEGF ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-VEGF antibody and an VEGF-HRP conjugate. The assay sample and buffer are incubated together with VEGF-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the VEGF concentration since VEGF from samples and VEGF-HRP conjugate compete for the anti-VEGF antibody binding site. Since the number of sites is limited, as more sites are occupied by VEGF from the sample, fewer sites are left to bind VEGF-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The VEGF concentration in each sample is interpolated from this standard curve.

181971

AAA35789.1

34,406 Da

Angiogenesis Pathway (198772); Axon Guidance Pathway (105688); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Cellular Response To Hypoxia Pathway (645259); Cellular Responses To Stress Pathway (645258); Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); Developmental Biology Pathway (477129); EPH-Ephrin Signaling Pathway (1016174)

This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms. [provided by RefSeq, Jul 2008]

48-Strip-Wells

470 USD

96-Strip-Wells

675